Lv1
20 积分 2023-07-10 加入
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
2天前
已完结
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
5天前
已完结
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
1个月前
已完结
OP0061 Kineret® (Anakinra) Controls Disease Symptoms in Patients with Severe Cryopyrin-Associated Periodic Syndromes (CAPS): Up to 5-Year Follow-Up Data
4个月前
已完结
Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification
5个月前
已完结
Application of estimand framework in ICH E9 (R1) to vaccine trials
10个月前
已完结
皖公网安备34019202002308
